Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Melanoma 2Thyroid Diseases 1Stomach Neoplasms 1Skin Neoplasms 1Neuroma, Acoustic 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Gastrointestinal Diseases 1Endometrial Neoplasms 1Brain Neoplasms 1Adenolymphoma 1

Interventions

aldesleukin 15Cyclophosphamide 15fludarabine phosphate 12fludarabine 11Interleukin-2 10Nivolumab 6Ipilimumab 6Temozolomide 5pembrolizumab 3Fluorouracil 3trametinib 2sonidegib 2dabrafenib 2binimetinib 2Whole-Body Irradiation 2Vemurafenib 2Tacrolimus 2Sodium Chloride 2Sirolimus 2Radiotherapy 2Radiation 2Peptides 2HhAntag691 2Gefitinib 2Dacarbazine 2Cyclosporine 2Cetuximab 2Capecitabine 2veliparib 1varlilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Skin Neoplasms × Fluorescein × Clear all
NCT00847522 2017-12-20

Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma

University of Utah

Phase 1/2 Completed
90 enrolled 7 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡